TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 176 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.28 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,179 | -24.3% | 131,891 | +90.4% | 0.01% | -27.8% |
| Q1 2023 | $1,558 | -99.8% | 69,260 | +105.9% | 0.02% | +100.0% |
| Q2 2022 | $815,000 | +32.7% | 33,635 | +41.1% | 0.01% | +80.0% |
| Q1 2022 | $614,000 | -35.4% | 23,845 | -22.2% | 0.01% | 0.0% |
| Q4 2021 | $951,000 | -21.9% | 30,644 | -39.0% | 0.01% | -16.7% |
| Q3 2021 | $1,217,000 | +476.8% | 50,197 | +246.4% | 0.01% | +500.0% |
| Q2 2021 | $211,000 | -64.7% | 14,492 | -39.5% | 0.00% | -66.7% |
| Q1 2021 | $598,000 | +19.8% | 23,967 | +30.9% | 0.00% | 0.0% |
| Q4 2020 | $499,000 | – | 18,315 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Deep Track Capital, LP | 7,370,000 | $113,203,200 | 5.24% |
| Finepoint Capital LP | 761,721 | $11,700,035 | 4.05% |
| Kynam Capital Management, LP | 1,454,730 | $22,344,653 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 441,019 | $6,769,642 | 2.06% |
| MPM BioImpact LLC | 552,846 | $8,491,715 | 1.71% |
| ARMISTICE CAPITAL, LLC | 7,450,000 | $114,432,000 | 1.66% |
| SECTORAL ASSET MANAGEMENT INC | 435,313 | $6,686,408 | 1.12% |
| Octagon Capital Advisors LP | 495,000 | $7,603,200 | 1.06% |
| Orbimed Advisors | 2,118,100 | $32,534,016 | 0.59% |
| Rock Springs Capital Management LP | 1,527,720 | $23,465,779 | 0.56% |